Last reviewed · How we verify
Intra articular injection with liposomal bupivacaine
Intra articular injection with liposomal bupivacaine is a Small molecule drug developed by Mayo Clinic. It is currently FDA-approved. Also known as: Exparel.
Intra articular injection with liposomal bupivacaine, marketed by Mayo Clinic, holds a position in the pain management segment for surgical patients. The key composition patent expires in 2028, providing a strong barrier to entry and maintaining competitive advantage during this period. The primary risk is the potential for increased competition post-patent expiry in 2028.
At a glance
| Generic name | Intra articular injection with liposomal bupivacaine |
|---|---|
| Also known as | Exparel |
| Sponsor | Mayo Clinic |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of Platelet-Rich Plasma Combined With Compound Betamethasone in Arthroscopic Surgery for Rotator Cuff Injury With Shoulder Adhesion: A Prospective, Multicenter, Randomized Controlled Trial (NA)
- A Sequenced Strategy for Improving Outcomes in People With Knee Osteoarthritis Pain (PHASE3)
- Adductor Canal Block With Periarticular Injection and IPACK (ACB/PAI/IPACK) Versus Periarticular Injection (PAI) (PHASE4)
- Adductor Canal Block Versus Liposomal Bupivacaine in TKA (PHASE4)
- Liposomal Bupivacaine in Total Knee Arthroplasty (NA)
- Peripheral Nerve Blocks vs Periarticular Local Anesthetic Injection for Total Knee Arthroplasty (TKA) (PHASE4)
- Peri-articular Injection Utilizing a Pain Cocktail With and Without Exparel (PHASE4)
- Serum Bupivacaine Concentration Levels After Injection of Liposomal Bupivacaine Into the Knee
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intra articular injection with liposomal bupivacaine CI brief — competitive landscape report
- Intra articular injection with liposomal bupivacaine updates RSS · CI watch RSS
- Mayo Clinic portfolio CI
Frequently asked questions about Intra articular injection with liposomal bupivacaine
What is Intra articular injection with liposomal bupivacaine?
Who makes Intra articular injection with liposomal bupivacaine?
Is Intra articular injection with liposomal bupivacaine also known as anything else?
What development phase is Intra articular injection with liposomal bupivacaine in?
Related
- Manufacturer: Mayo Clinic — full pipeline
- Also known as: Exparel
- Compare: Intra articular injection with liposomal bupivacaine vs similar drugs
- Pricing: Intra articular injection with liposomal bupivacaine cost, discount & access